3,4-Dimethylmethcathinone

3,4-Dimethylmethcathinone
Clinical data
ATC code
  • none
Legal status
Legal status
  • DE: Anlage II (Authorized trade only, not prescriptible)
  • UK: Class B
Identifiers
IUPAC name
  • (±)-1-(3,4-Dimethylphenyl)-2-(methylamino)propan-1-one
CAS Number
PubChem CID
ChemSpider
UNII
Chemical and physical data
FormulaC12H17NO
Molar mass191.274 g·mol−1
3D model (JSmol)
SMILES
  • Cc1ccc(C(=O)C(C)NC)cc1C
InChI
  • InChI=1S/C12H17NO/c1-8-5-6-11(7-9(8)2)12(14)10(3)13-4/h5-7,10,13H,1-4H3 checkY
  • Key:IBZRXTVDTGVBIS-UHFFFAOYSA-N checkY
 ☒NcheckY (what is this?)  (verify)

3,4-Dimethylmethcathinone (3,4-DMMC) is a stimulant drug first reported in 2010 as a designer drug analogue of mephedrone, apparently produced in response to the banning of mephedrone, following its widespread abuse in many countries in Europe and around the world.[1] 3,4-DMMC has been seized as a designer drug in Australia.[2] In vitro, 3,4-DMMC was shown to be a monoamine transporter substrate that potently inhibits norepinephrine and serotonin reuptake, and to a lesser extent dopamine reuptake.[3]

As of October 2015 3,4-DMMC is a controlled substance in China.[4]

3,4-DMMC is banned in the Czech Republic.[5]

See also

References

  1. EMCDDA Annual Report 2010
  2. Locos O, Reynolds D (September 2012). "The characterization of 3,4-dimethylmethcathinone (3,4-DMMC)". Journal of Forensic Sciences. 57 (5): 1303–6. doi:10.1111/j.1556-4029.2012.02142.x. PMID 22564211. S2CID 205770717.
  3. Luethi D, Kolaczynska KE, Docci L, Krähenbühl S, Hoener MC, Liechti ME (2018). "Pharmacological profile of mephedrone analogs and related new psychoactive substances" (PDF). Neuropharmacology. 15 (134): 4–12. doi:10.1016/j.neuropharm.2017.07.026. PMID 28755886. S2CID 28786127.
  4. "关于印发《非药用类麻醉药品和精神药品列管办法》的通知" (in Chinese). China Food and Drug Administration. 27 September 2015. Archived from the original on 1 October 2015. Retrieved 1 October 2015.
  5. "Látky, o které byl doplněn seznam č. 4 psychotropních látek (příloha č. 4 k nařízení vlády č. 463/2013 Sb.)" (PDF) (in Czech). Ministerstvo zdravotnictví.
This article is issued from Offline. The text is licensed under Creative Commons - Attribution - Sharealike. Additional terms may apply for the media files.